EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) — EPIX

Metastatic Castration Resistant Prostate Cancer (mCRPC) Clinical Trial

Official title:
Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo): Patient Characteristics and Predictors of Long-term Survival

Status Completed

Clinical Trial Summary

In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Metastatic Castration Resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT04516161
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase
Start date	August 3, 2020
Completion date	March 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT05208229` - The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
Suspended	`NCT05425862` - Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer	Phase 1
Active, not recruiting	`NCT03480646` - ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer	Phase 1/Phase 2
Recruiting	`NCT03874884` - 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer	Phase 1
Terminated	`NCT03549000` - A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.	Phase 1
Completed	`NCT05701007` - Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Terminated	`NCT04052204` - Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03724747` - Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer	Phase 1
Withdrawn	`NCT02130947` - Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide	N/A